Literature DB >> 3428284

Comparative tumour localization properties of radiolabelled monoclonal antibody preparations of defined immunoreactivities.

M V Pimm1, R W Baldwin.   

Abstract

The immunoreactive fraction of an anti-CEA monoclonal antibody preparation has been progressively decreased by the addition of increasing proportions of impurity in the form of immunologically inert mouse immunoglobulin. Following radioiodination, the immunoreactive fractions of the preparations were determined and their localization in a human tumour xenograft in nude mice was assessed. There was a progressive decline in tumour localization, from tumour to blood ratios of 2:1 with unadulterated antibody to 0.6:1 with preparations only 15% with respect to the initial antibody. These findings demonstrate that the immunoreactive fraction of monoclonal antibody preparations is a major limiting factor in tumour localization and this has implications for experimental and clinical applications of monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428284     DOI: 10.1007/BF00252993

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  15 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies.

Authors:  P L Beaumier; D Neuzil; H M Yang; E A Noll; R Kishore; J F Eary; K A Krohn; W B Nelp; K E Hellström; I Hellström
Journal:  J Nucl Med       Date:  1986-06       Impact factor: 10.057

3.  The preparation and characterisation of 111In-labelled 791T/36 monoclonal antibody for tumour immunoscintigraphy.

Authors:  A C Perkins; M V Pimm; M K Birch
Journal:  Eur J Nucl Med       Date:  1985

4.  Use of the direct linear plot to estimate, in an immunoglobulin solution, the proportion which is specific monoclonal antibody against an unknown cell surface antigen.

Authors:  C S Partridge; D W Britton; K D Bagshawe
Journal:  J Immunol Methods       Date:  1985-04-08       Impact factor: 2.303

5.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

6.  A new and rapid method for immunoglobulin class and subclass determination of mouse monoclonal antibodies using a solid-phase immunoradiometric assay.

Authors:  M J Storch; M L Lohmann-Matthes
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

7.  In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts.

Authors:  M V Pimm; M J Embleton; A C Perkins; M R Price; R A Robins; G R Robinson; R W Baldwin
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

8.  Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing nude mice.

Authors:  J Y Douillard; J F Chatal; J C Saccavini; C Curtet; M Kremer; P Peuvrel; H Koprowski
Journal:  Eur J Nucl Med       Date:  1985

9.  Carcinoembryonic antigen production in human gastric cancer cell lines in vitro and in nude mice.

Authors:  T Motoyama; H Watanabe
Journal:  Gan       Date:  1983-10

10.  Diverse characteristics of 111In labelled anti-CEA monoclonal antibodies for tumour immunoscintigraphy: radiolabelling, biodistribution and imaging studies in mice with human tumour xenografts.

Authors:  M V Pimm; A C Perkins; R W Baldwin
Journal:  Eur J Nucl Med       Date:  1987
View more
  2 in total

Review 1.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Radiolocalisation and imaging of stably HPLAP-transfected MO4 tumours with monoclonal antibodies and fragments.

Authors:  P G Hendrix; S E Dauwe; A Van De Voorde; E J Nouwen; M F Hoylaerts; M E De Broe
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.